Ranibizumab biosimilar - BIOCND

Drug Profile

Ranibizumab biosimilar - BIOCND

Alternative Names: BCD 300; QL 1205

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BIOCND
  • Developer BIOCND; Qilu Pharmaceutical
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Macular degeneration; Wet age-related macular degeneration

Most Recent Events

  • 01 Oct 2017 Phase-I clinical trials in Wet age-related macular degeneration in China (IV) (NCT03312283)
  • 26 Jul 2017 Phase-I clinical trials in Macular degeneration in South Korea (unspecified route) (BIOCND pipeline, July 2017)
  • 26 Jul 2017 BIOCND announces intention to submit marketing authorisation for Macular degenration in 2020 (BIOCND pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top